Uppsala Monitoring Centre

Uppsala Monitoring Centre (UMC) operates as the World Health Organization Collaborating Centre for International Drug Monitoring, providing the global infrastructure for pharmacovigilance activities. Its core service is the maintenance of VigiBase, the WHO Global Individual Case Safety Report database that aggregates adverse reaction reports from member countries. UMC also delivers a suite of software tools that enable national centres and other stakeholders to manage, analyse, and exchange safety data, including VigiFlow for case processing, VigiLyze for data exploration and signal detection, and WHODrug Insight for medication coding and classification. In addition to these platforms, the organisation offers specialised reporting modules such as Vaccine eReporting and primary eReporting functions that support timely submission of safety information. These services are utilised by national pharmacovigilance centres, regulatory agencies, pharmaceutical companies, academic researchers, and other entities involved in drug safety monitoring worldwide. By standardising data collection and facilitating cross‑border communication, UMC helps ensure that safety signals are identified and evaluated consistently across different jurisdictions.

Although the prompt does not disclose specific figures for staff size or annual budget, UMC’s reach is evident through its role as the central hub for the WHO’s international drug monitoring network, which encompasses numerous countries and territories. The organisation is distinguished by its exclusive focus on drug safety and its mandate to support global pharmacovigilance under the auspices of the WHO, a role that confers both technical authority and neutrality. Its notable competencies include the curation of large‑scale safety databases, the development of validated signal‑detection methodologies, and the provision of training and guidance to improve reporting quality across diverse health systems. Structurally, UMC is organised as a non‑profit foundation established under Swedish law, with its headquarters located in Uppsala, Sweden, and it operates under the oversight of a board that represents WHO member states and other stakeholders. This foundation status allows it to reinvest any surplus into service improvements and capacity‑building initiatives rather than distributing profits. The January 2024 cyber‑attack on its IT provider Tietoevry, which disrupted services such as VigiFlow, VigiLyze, WHODrug Insight and user access portals while sparing Vaccine eReporting and primary eReporting, underscored the critical dependence of global pharmacovigilance on resilient IT infrastructure and prompted UMC to activate a crisis team to coordinate recovery and communication.